Source link : https://newshealth.biz/health-news/dual-immunotherapy-improves-dfs-in-resectable-kidney-cancer/
SAN FRANCISCO — Adjuvant durvalumab (Imfinzi) and tremelimumab (Imjudo) improved disease-free survival (DFS) in a phase III trial of resectable renal cell carcinoma (RCC), but researchers here said the regimen’s impact on quality of life (QoL) should be taken into consideration. In the RAMPART trial, 3-year DFS improved from 73% with active monitoring following tumor […]
The post Dual Immunotherapy Improves DFS in Resectable Kidney Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-03-03 17:20:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8